We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

17 hedge funds and large institutions have $144K invested in Sonoma Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

13% more funds holding

Funds holding: 15 → 17 (+2)

0.07% less ownership

Funds ownership: 0.23% → 0.16% (-0.07%)

10% less capital invested

Capital invested by funds: $159K → $144K (-$15.8K)

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$20.7K
2
GSC
Ground Swell Capital
South Carolina
+$17.2K
3
Millennium Management
Millennium Management
New York
+$9K
4
ASN
Advisory Services Network
Georgia
+$3.17K
5
JP Morgan Chase
JP Morgan Chase
New York
+$876

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$41.9K
2
UBS Group
UBS Group
Switzerland
-$3.28K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$696
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$41K -$41.9K -1,625 -44%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$35.4K -$696 -27 -1%
Millennium Management
3
Millennium Management
New York
$23K +$9K +349 +42%
VF
4
Virtu Financial
New York
$16K +$20.7K +803 New
GSC
5
Ground Swell Capital
South Carolina
$13K +$17.2K +666 New
TRCT
6
Tower Research Capital (TRC)
New York
$8K +$670 +26 +6%
BlackRock
7
BlackRock
New York
$2.81K – – –
ASN
8
Advisory Services Network
Georgia
$2.4K +$3.17K +123 New
JP Morgan Chase
9
JP Morgan Chase
New York
$1K +$876 +34 New
US Bancorp
10
US Bancorp
Minnesota
$488 – – –
Osaic Holdings
11
Osaic Holdings
Arizona
$210 +$77 +3 +38%
Morgan Stanley
12
Morgan Stanley
New York
$84 – – –
AF
13
Allworth Financial
California
$64 – – –
Bank of America
14
Bank of America
North Carolina
$43 – – –
GI
15
Gradient Investments
Minnesota
$30 – – –
Wells Fargo
16
Wells Fargo
California
$21 – – –
NC
17
NewSquare Capital
Pennsylvania
$10 – – –
UBS Group
18
UBS Group
Switzerland
– -$3.28K -146 Closed

SNOA Hedge Fund Activity: Q1 2023 in Review

17 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2023, worth a combined $144K — down 9.9% from $159K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SNOA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $20.7K. The largest seller was Renaissance Technologies, cutting an estimated $41.9K.

  • 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2023, up from 15 in Q4 2022.
  • Funds reported $144K of Sonoma Pharmaceuticals stock for Q1 2023, down 9.9% quarter-over-quarter.
  • 4 funds opened new Sonoma Pharmaceuticals positions in Q1 2023 and 2 closed out, a net change of +2 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q1 2023 was Virtu Financial, an estimated $20.7K added.
  • The largest Sonoma Pharmaceuticals seller in Q1 2023 was Renaissance Technologies, an estimated $41.9K sold.

Based on aggregated 13F filings for Q1 2023.